Cargando…

A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland

BACKGROUND: A two-dose preoperative vaccination schedule against HBV has been the widely accepted policy in Poland. However, its effectiveness has not yet been assessed. Objective: To evaluate a two-dose preoperative HBV vaccination policy by an assessment of the proportion of patients who don’t pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganczak, Maria, Korzen, Marcin, Jurewicz, Alina, Szych, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526288/
https://www.ncbi.nlm.nih.gov/pubmed/28743234
http://dx.doi.org/10.1186/s12879-017-2607-2
_version_ 1783252784348397568
author Ganczak, Maria
Korzen, Marcin
Jurewicz, Alina
Szych, Zbigniew
author_facet Ganczak, Maria
Korzen, Marcin
Jurewicz, Alina
Szych, Zbigniew
author_sort Ganczak, Maria
collection PubMed
description BACKGROUND: A two-dose preoperative vaccination schedule against HBV has been the widely accepted policy in Poland. However, its effectiveness has not yet been assessed. Objective: To evaluate a two-dose preoperative HBV vaccination policy by an assessment of the proportion of patients who don’t present a protective level of anti-HBs (<10.0 mIU/ml). METHODS: Consecutive patients from surgical/gynecologic wards of 12 randomly selected hospitals in West Pomerania, Poland, hospitalized between 2010 and 2013, vaccinated against HBV with a two-dose regimen, were asked to complete an anonymous questionnaire. Serum samples were assayed for anti-HBs with the use of third-generation testing methods. To compare sensitivity versus specificity across a range of values for the ability to predict a dichotomous outcome (a protection against HBV infection) a Receiver operating characteristic (ROC) curve was determined. RESULTS: There were 193 patients, 58.5% women, median age 52 years. Almost a half (46.0%) of the patients were operated on within 0–60 days of taking the second vaccine dose, 16.2% - 61-180 days after, 37.8% >180 days after. Anti-HBs titer was below a protective level in 49.2% of participants (0.0 mIU/ml in 17.8%, 0.1–9.9 mIU/ml in 31.4%); none of them were aware of this fact. Age ≤ 52 years (OR = 1.89) and having surgery more than 37.5 days after HBV vaccination (OR = 2.70) were associated with greater odds of being protected against HBV infection through vaccination. For the time frame between the second dose implementation and surgery 23 days, a sensitivity of 84% and specificity of 22% for obtaining protection against HBV infection was found, for the time frame >37.5 days – sensitivity remained high (80%), while specificity increased (41%); there was an apparent peek on the ROC curve between 38 and 60 day. In the group vaccinated 0–37.5 days before surgery, less patients had the protective level of anti-HBs titer than in vaccinated 38–60 days before surgery (32.3% vs 60.0%; p = 0.03). CONCLUSIONS: The success rate in achieving adequate immune protection with two dose HBV vaccination schedule in preoperatively vaccinated patients is relatively low, especially among those vaccinated less than five weeks prior to surgery. In more than a third of cases the standard three-dose regimen could have been implemented, as participants had time to complete a third dose. Current recommendations regarding a preoperative policy with a 2-dose vaccination schedule in Poland should be revised; the best time to perform surgery after the implementation of the second dose of vaccine in the context of patient protection against HBV infection would be between 38 and 60 days.
format Online
Article
Text
id pubmed-5526288
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55262882017-08-02 A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland Ganczak, Maria Korzen, Marcin Jurewicz, Alina Szych, Zbigniew BMC Infect Dis Research Article BACKGROUND: A two-dose preoperative vaccination schedule against HBV has been the widely accepted policy in Poland. However, its effectiveness has not yet been assessed. Objective: To evaluate a two-dose preoperative HBV vaccination policy by an assessment of the proportion of patients who don’t present a protective level of anti-HBs (<10.0 mIU/ml). METHODS: Consecutive patients from surgical/gynecologic wards of 12 randomly selected hospitals in West Pomerania, Poland, hospitalized between 2010 and 2013, vaccinated against HBV with a two-dose regimen, were asked to complete an anonymous questionnaire. Serum samples were assayed for anti-HBs with the use of third-generation testing methods. To compare sensitivity versus specificity across a range of values for the ability to predict a dichotomous outcome (a protection against HBV infection) a Receiver operating characteristic (ROC) curve was determined. RESULTS: There were 193 patients, 58.5% women, median age 52 years. Almost a half (46.0%) of the patients were operated on within 0–60 days of taking the second vaccine dose, 16.2% - 61-180 days after, 37.8% >180 days after. Anti-HBs titer was below a protective level in 49.2% of participants (0.0 mIU/ml in 17.8%, 0.1–9.9 mIU/ml in 31.4%); none of them were aware of this fact. Age ≤ 52 years (OR = 1.89) and having surgery more than 37.5 days after HBV vaccination (OR = 2.70) were associated with greater odds of being protected against HBV infection through vaccination. For the time frame between the second dose implementation and surgery 23 days, a sensitivity of 84% and specificity of 22% for obtaining protection against HBV infection was found, for the time frame >37.5 days – sensitivity remained high (80%), while specificity increased (41%); there was an apparent peek on the ROC curve between 38 and 60 day. In the group vaccinated 0–37.5 days before surgery, less patients had the protective level of anti-HBs titer than in vaccinated 38–60 days before surgery (32.3% vs 60.0%; p = 0.03). CONCLUSIONS: The success rate in achieving adequate immune protection with two dose HBV vaccination schedule in preoperatively vaccinated patients is relatively low, especially among those vaccinated less than five weeks prior to surgery. In more than a third of cases the standard three-dose regimen could have been implemented, as participants had time to complete a third dose. Current recommendations regarding a preoperative policy with a 2-dose vaccination schedule in Poland should be revised; the best time to perform surgery after the implementation of the second dose of vaccine in the context of patient protection against HBV infection would be between 38 and 60 days. BioMed Central 2017-07-25 /pmc/articles/PMC5526288/ /pubmed/28743234 http://dx.doi.org/10.1186/s12879-017-2607-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ganczak, Maria
Korzen, Marcin
Jurewicz, Alina
Szych, Zbigniew
A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title_full A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title_fullStr A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title_full_unstemmed A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title_short A cross-sectional sero-survey on preoperative HBV vaccination policy in Poland
title_sort cross-sectional sero-survey on preoperative hbv vaccination policy in poland
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526288/
https://www.ncbi.nlm.nih.gov/pubmed/28743234
http://dx.doi.org/10.1186/s12879-017-2607-2
work_keys_str_mv AT ganczakmaria acrosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT korzenmarcin acrosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT jurewiczalina acrosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT szychzbigniew acrosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT ganczakmaria crosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT korzenmarcin crosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT jurewiczalina crosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland
AT szychzbigniew crosssectionalserosurveyonpreoperativehbvvaccinationpolicyinpoland